

Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study

Oct 09, 2018

Source URL: <https://qa1.novartis.us/news/media-releases/novartis-analysis-shows-crizanlizumab-seg101-increased-number-patients-free-sickle-cell-pain-crisis-vs-placebo-during-sustain-study-0>

List of links present in page

1. <https://qa1.novartis.us/news/media-releases/novartis-analysis-shows-crizanlizumab-seg101-increased-number-patients-free-sickle-cell-pain-crisis-vs-placebo-during-sustain-study-0>